Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Anticorps > Anticorps Primaires

Anti-TNFRSF11B Polyclonal Antibody (HT419014)

Prix(USD) :
Spécification :
  • 50ug
  • 100ug
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHT419014
Reactivité des espècesHuman
ApplicationsELISA, IHC, WB
Espèce hôteRabbit
ClonalitéPolyclonal
IsotypeIgG
Immunogène E. coli - derived recombinant Human TNFRSF11B (Thr76-Lys317).
Cible OPG, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, OCIF
Niveau d'endotoxines Please contact with the lab for this information.
Purification Purified by antigen affinity column.
Numéro d'accès O00300
Forme Liquid
Tampon de stockage 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit
Application Dilution
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Contexte

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is a ~46 kDa protein. Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis.

Reférences 1. Dutka M, et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart failure reviews. 2022 Jul;27(4):1395-1411. [HT419014]
2. Payr S, et al. Direct comparison of 3D and 2D cultivation reveals higher osteogenic capacity of elderly osteoblasts in 3D. Journal of orthopaedic surgery and research. 2021 Jan 06;16(1):13. [HT419014]
Note For research use only.
Images
Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs